Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9;8(1):40.
doi: 10.1186/s40662-021-00264-0.

Five-year outcomes of EVO implantable collamer lens implantation for the correction of high myopia and super high myopia

Xun Chen #  1   2   3 , Xuanqi Wang #  1   2   3 , Yilin Xu  1   2   3 , Mingrui Cheng  1   2   3 , Tian Han  1   2   3 , LingLing Niu  1   2   3 , Xiaoying Wang  4   5   6 , Xingtao Zhou  7   8   9
Affiliations

Five-year outcomes of EVO implantable collamer lens implantation for the correction of high myopia and super high myopia

Xun Chen et al. Eye Vis (Lond). .

Abstract

Background: To evaluate the long-term safety, efficacy, predictability, and stability of implantable collamer lens with a central hole (EVO ICL) implantation for correcting high myopia (HM) and super high myopia (SHM).

Methods: This prospective study evaluated 83 eyes of 46 patients who were divided into groups based on their spherical equivalent refractive error (SE): HM group (- 12 D ≤ SE < - 6 D) and SHM group (SE < - 12 D). They were followed up for 5 years after ICL implantation; assessments of uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refractive error, axial length, intraocular pressure, corneal endothelial cell density, and vault were conducted, and a questionnaire was administered.

Resuits: At 5 years postoperatively, the safety indices of the HM and SHM groups were 1.03 ± 0.10 and 1.32 ± 0.39, and the efficacy indices were 0.83 ± 0.25 and 0.86 ± 0.32, respectively. In the HM group, 60.47% and 79.07% of the eyes were within ± 0.50 D and ± 1.00 D of the attempted correction, while it was achieved for 22.50% and 47.50% of the eyes in the SHM group, respectively. The SE of the HM group decreased from - 9.72 ± 1.41 D preoperatively to 0.04 ± 0.39 D 1 month postoperatively and - 0.67 ± 0.57 D 5 years postoperatively, while in the SHM group, it decreased from - 15.78 ± 3.06 D preoperatively to - 0.69 ± 0.97 D 1 month postoperatively and - 1.74 ± 1.19 D 5 years postoperatively.

Conclusion: EVO ICL implantation is safe, effective, and predictable for correcting HM and SHM. CDVA improved more after surgery for SHM, but the growth of axial length still needs attention.

Keywords: EVO ICL; High myopia; Posterior chamber phakic intraocular lens implantation; Super high myopia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The percentage of eyes that gained/lost lines of CDVA at different time points of follow-up after EVO implantable collamer lens implantation between high myopia (HM) and super high myopia (SHM) groups. m, month; y, year
Fig. 2
Fig. 2
The cumulative percentage of UDVA at different time points after EVO implantable collamer lens implantation between high myopia (HM) and super high myopia (SHM) groups. m, month; y, year
Fig. 3
Fig. 3
Scatter plot of attempted versus achieved correction (spherical equivalent) after EVO implantable collamer lens implantation between high myopia (HM) (a) and super high myopia (SHM) (b) groups. The black solid line represents achieved correction = attempted correction, the black dotted line represents achieved correction = attempted correction ± 1.00 D. m, month; y, year
Fig. 4
Fig. 4
Manifest spherical equivalent (a) and axial length (b) between high myopia (HM) and super high myopia (SHM) groups after implantation of EVO implantable collamer lens over time. m, month; y, year; pre, preoperative
Fig. 5
Fig. 5
Intraocular pressure (a), vault (b) and the endothelial cell density (c) between high myopia (HM) and super high myopia (SHM) groups during the period of follow-up after implantation of EVO implantable collamer lens. m, month; y, year; pre, preoperative
See this image and copyright information in PMC

References

    1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–1042. doi: 10.1016/j.ophtha.2016.01.006. - DOI - PubMed
    1. Wang J, Ying GS, Fu X, Zhang R, Meng J, Gu F, et al. Prevalence of myopia and vision impairment in school students in Eastern China. BMC Ophthalmol. 2020;20(1):2. doi: 10.1186/s12886-019-1281-0. - DOI - PMC - PubMed
    1. Choi JH, Lim DH, Nam SW, Yang CM, Chung ES, Chung TY. Ten-year clinical outcomes after implantation of a posterior chamber phakic intraocular lens for myopia. J Cataract Refract Surg. 2019;45(11):1555–1561. doi: 10.1016/j.jcrs.2019.06.015. - DOI - PubMed
    1. Dishler JG, Slade S, Seifert S, Schallhorn SC. Small-incision lenticule extraction (SMILE) for the correction of myopia with astigmatism: outcomes of the United States Food and Drug Administration Premarket approval clinical trial. Ophthalmology. 2020;127(8):1020–1034. doi: 10.1016/j.ophtha.2020.01.010. - DOI - PubMed
    1. Siedlecki J, Schmelter V, Mayer WJ, Schworm B, Priglinger SG, Dirisamer M, et al. SMILE versus implantable Collamer lens implantation for high myopia: a matched comparative study. J Refract Surg. 2020;36(3):150–159. doi: 10.3928/1081597X-20200210-02. - DOI - PubMed

LinkOut - more resources